```html

Joubert‑Plus Syndrome: A Complete Patient‑Friendly Guide

Overview

Joubert‑Plus syndrome (JPS) is a rare, multisystem neurodevelopmental disorder that combines the classic features of Joubert syndrome (JS) with additional organ involvement such as retinal dystrophy, liver disease, or kidney anomalies. The condition is caused by pathogenic variants in genes that encode proteins essential for primary cilia function, making it part of the broader group of ciliopathies.

• Who it affects: Both males and females are affected, with onset evident at birth or in early infancy.
• Prevalence: Joubert syndrome occurs in approximately 1 in 80,000–100,000 live births; Joubert‑Plus syndromes are even rarer, representing about 10‑20% of all JS cases (estimated < 1 per 500,000 births) 【1】.
• Geographic distribution: Cases have been reported worldwide, with slightly higher rates in populations with higher rates of consanguineous marriage.

Symptoms

Symptoms are variable, reflecting the specific gene mutation and which organs are involved. Below is a comprehensive list with brief descriptions.

Neurological Features (present in >95% of cases)

• Molor brainstem‑cerebellar “molar tooth sign” on MRI – the hallmark radiologic finding.
Hypotonia (reduced muscle tone) in infancy, progressing to ataxia and gait instability.
• Developmental delay – delayed milestones such as sitting, crawling, and speech.
• Abnormal breathing patterns – episodic tachypnea or apnea, especially during sleep.
• Ocular motor apraxia – difficulty initiating eye movements.
• Intellectual disability – ranging from mild to severe.

Ophthalmologic Involvement (seen in ~30‑50% of JPS)

• Retinal dystrophy (Leber congenital amaurosis or rod–cone dystrophy) leading to reduced visual acuity.
• Coloboma, nystagmus, or strabismus.

Renal Manifestations (≈20‑30%)

• Cysts or dysplasia causing chronic kidney disease.
• Nephronophthisis‑type renal failure, often presenting in childhood or adolescence.

Hepatic Involvement (≈10‑15%)

• Congenital liver fibrosis or cholestasis.
• Elevated liver enzymes; risk of portal hypertension.

Other Possible Features

• Polydactyly (extra fingers or toes) – seen in some genetic subtypes.
• Facial dysmorphism (frontal bossing, arched eyebrows).
• Cardiac defects (ventricular septal defect, atrial septal defect) – rare but reported.
• Skeletal anomalies (such as scoliosis) in later childhood.

Causes and Risk Factors

Joubert‑Plus syndrome is inherited in an autosomal recessive or, less commonly, autosomal dominant pattern, depending on the gene involved. More than 30 genes have been linked to JS and its plus variants, the most common being TMEM67, CEP290, AHI1, OFD1, and TMEM216.

• Genetic mutation: Loss‑of‑function variants impair the structure or signaling of primary cilia, which are critical for organ development.
• Consanguinity: Families with close genetic relatedness have a higher carrier frequency.
• Family history: Having a sibling or parent with Joubert or related ciliopathies increases risk.
• Ethnicity: Certain founder mutations are more common in specific populations (e.g., Finnish, French‑Canadian).

Diagnosis

Diagnosis combines clinical assessment, imaging, and genetic testing.

Clinical Evaluation

• Detailed developmental and neurological exam.
• Assessment of vision, hearing, renal and hepatic function.

Neuroimaging

The “molar tooth sign” on a brain MRI (T2‑weighted axial view) is pathognomonic. Additional findings may include vermian hypoplasia and thickened superior cerebellar peduncles.

Genetic Testing

• Targeted gene panels for Joubert/ciliopathy genes (most cost‑effective).
• Whole‑exome sequencing (WES) when panel is negative but suspicion remains.
• Parental carrier testing is recommended after a diagnosis is confirmed.

Ancillary Tests

• Ophthalmologic exam (electroretinogram, fundus photography).
• Renal ultrasound and serum creatinine to evaluate kidney structure/function.
• Liver function tests and abdominal MRI if hepatic disease is suspected.
• Polysomnography for breathing abnormalities during sleep.

Treatment Options

There is no cure; management focuses on symptom control, preventing complications, and supporting development.

Neurological Management

• Physical and occupational therapy – essential for improving muscle tone, balance, and motor skills.
• Speech therapy – addresses language delays and oral‑motor dysfunction.
• Medications for abnormal breathing – low‑dose caffeine or theophylline may reduce apnea episodes (off‑label use, discuss with a neurologist).
• Anti‑seizure drugs when epilepsy co‑exists (e.g., levetiracetam, valproate).

Ophthalmologic Care

• Low‑vision aids, vision therapy, and regular retinal monitoring.
• Gene‑specific therapies are under investigation (e.g., AAV‑mediated CEP290 therapy for related retinal disease).

Renal Management

• Hydration, low‑salt diet, and blood pressure control.
• Monitoring eGFR every 6‑12 months; early referral to a nephrologist.
• Renal transplantation is an option for end‑stage disease.

Hepatic Management

• Periodic liver enzymes and ultrasound.
• Ursodeoxycholic acid for cholestasis (based on hepatology guidance).
• Management of portal hypertension (beta‑blockers, endoscopic variceal ligation if needed).

Medication & Procedural Interventions

• Vitamin D and calcium supplementation for bone health.
• Orthopedic surgery for severe scoliosis or joint contractures, when indicated.
• Ventilatory support (CPAP or BiPAP) for persistent sleep‑disordered breathing.

Lifestyle and Supportive Measures

• Balanced nutrition with attention to caloric needs (some children have feeding difficulties).
• Regular exercise adapted to ability level – improves motor function and respiratory health.
• Psychosocial support for families – counseling, support groups, and educational advocacy.

Living with Joubert‑Plus Syndrome

Successful long‑term management relies on a coordinated, multidisciplinary approach.

Practical Daily‑Management Tips

1. Establish a routine – predictable schedules aid children with cognitive and motor challenges.
2. Use adaptive equipment – e.g., gait trainers, weighted blankets for proprioceptive input.
3. Monitor breathing – keep a log of apnea episodes; consider a home pulse‑oximeter.
4. Vision accommodations – high‑contrast books, large fonts, and screen magnifiers.
5. Kidney and liver checks – schedule labs and imaging as advised; keep a health‑record binder.
6. Educational planning – work with school’s IEP team; request occupational/physical therapy services.
7. Family self‑care – caregivers should seek respite care, mental‑health resources, and peer support.

Resources

• Joubert Syndrome Foundation – patient education and community forums.
• National Organization for Rare Disorders (NORD) – information on genetic counseling.
• Local rare‑disease clinics (often housed within tertiary academic hospitals).

Prevention

Because JPS is genetic, primary prevention focuses on reducing the chance of inheriting pathogenic variants.

• Carrier screening for at‑risk couples (especially those with consanguineous backgrounds) via pre‑conception or prenatal testing.
• Genetic counseling – discuss recurrence risk (25% for autosomal recessive, 50% for dominant) and reproductive options (PGD, donor gametes, adoption).
• Prenatal diagnosis – chorionic villus sampling or amniocentesis with targeted gene analysis if a known family mutation exists.

Complications

If left untreated or inadequately managed, JPS can lead to serious health issues:

• Progressive kidney failure requiring dialysis or transplantation.
• Severe visual impairment or blindness.
• Hepatic cirrhosis and portal hypertension.
• Recurrent respiratory infections due to impaired airway protective reflexes.
• Failure to thrive stemming from feeding difficulties and metabolic demands.
• Neurodevelopmental regression if seizures or severe apnea are uncontrolled.

When to Seek Emergency Care

References

1. Mayo Clinic. Joubert Syndrome. Accessed May 2026.
2. National Institutes of Health. Genetics Home Reference. Joubert syndrome. 2024.
3. Wang, Y. et al. “Ciliopathies and Jou bert syndrome spectrum: genotype‑phenotype correlations.” Nature Reviews Neurology, 2022.
4. Cleveland Clinic. Joubert Syndrome. 2023.
5. World Health Organization. Rare Diseases. 2021.
6. Joubert Syndrome Foundation. Clinical Guidelines. 2024.

```